By Plenary Sessions: Irja Lutsar

Demonstrates deep expertise in pharmaceutical policy and supply chains, utilizing specific terminology such as "ambulatory network," "rare diseases," and "radiopharmaceuticals." References previous regulatory discussions (five years ago) and analyses by the Competition Authority, and also provides examples from Finnish practice. It details the distinctions between wholesale and retail drug sales, as well as the bureaucracy associated with applying for marketing authorization.

The speaker demonstrates expertise in the operational structure of the Social Affairs Committee and the specifics of mental health service financing. They cover technical aspects, such as the formulas used for calculating funding (population-based, floor/ceiling limits) and issues related to co-payments. Furthermore, they are familiar with the plans of the Ministry of Social Affairs (SOM), including the development of the youth mental health action plan.

The expertise is evident in the domain of social policy and legislation, particularly at the intersection of social work intervention mechanisms and data protection. The speaker refers to specific details, such as the four diagnoses that trigger intervention, and is aware of the work of the social committee.